Vericel (VCEL) Misses Q4 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. SPY
8. XYZ
9. ANET
10. CVS

Go back to Vericel (VCEL) Misses Q4 EPS by 13c

Vericel Reports Fourth-Quarter and Year-End 2015 Financial Results

March 14, 2016 7:45 AM EDT

Total Revenues of $15.4 Million Reported for the Fourth Quarter

Conference Call Today at 8:00am Eastern Time

CAMBRIDGE, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2015.  Recent Business HighlightsDuring and since the fourth quarter of 2015, the company:

Announced positive top-line results from the Phase 2b ixCELL-DCM clinical... More